Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

Inclusion Criteria: * male and female ages 18 and 65 y.o. * BMI Body weight within a body mass index range of 17 - 30 kg/m2 (inclusive). Exclusion Criteria: * Hypersensitivity to the active substance of SLx-2101or to any of the excipients. * Past or present disease that is judged by the Investigator to have the potential to interfere with the study procedures, compromise safety, or affect the pharmacokinetic and pharmacodynamic evaluations